NEW HAVEN, Conn., Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant ( ARV-471 ) have been accepted for ...

ARVN

<p>康涅狄格州纽黑文，2025 年 11 月 24 日（GLOBE NEWSWIRE）-- Arvinas, Inc.（纳斯达克：ARVN），一家临床阶段的生物技术公司，正在开发基于靶向蛋白降解的新型药物，今天宣布关于 vepdegestrant（ARV-471）的多个摘要已被接受用于</p>

Arvinas Announces Data Presentations from the Vepdegestrant  ( ARV-471 )  Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium  ( SABCS ) 

Arvinas 宣布将在 2025 年圣安东尼奥乳腺癌研讨会上展示 Vepdegestrant（ARV-471）临床开发计划的数据